Multi-organ dysfunction associated with high-dose carboplatin therapy prior to autologous transplantation

Bone Marrow Transplantation

Volumn 17, Issue 1, 1996, Pages 67-74

  Grigg, A ^a   Szer, J ^a   Skov, K ^b   Barnett, M ^c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Autologous BMT; Carboplatin; Organ dysfunction

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; IFOSFAMIDE; PLATINUM;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL FEATURE; CREATININE CLEARANCE; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE EXCITABILITY; HUMAN; HYPOKINESIA; MALE; MENTAL DISEASE; MULTIPLE ORGAN FAILURE; MYOPATHY; NEUROLOGIC DISEASE; PATIENT MONITORING; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CARBOPLATIN; FEMALE; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030034036     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT et al. Carboplatin in combination chemotherapy for advanced ovarian cancer. Cancer Treat Rev 1988; 15: 9-15.
2. Horwich A. Carboplatin in the treatment of testicular cancer: The Royal Marsden Hospital Testicular Tumour Unit experience. In: Bunn PA, Canetta R, Ozols RF et al (eds). Carboplatin: Current Perspectives and Future Directions. Saunders: Philadelphia, 1990, pp 53-62.
3. Ayash LJ, Elias A, Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
4. Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651-661.
5. Pico JL, Ibrahim A, Castagna L et al. Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumours. Oncology 1993; 50 (suppl. 2): 47-52.
6. Linkesch W, Wagner A. Krainer M. Phase I/II trial of ultra high-dose chemotherapy with ABMT in refractory or relapsed non-seminomatous germ cell tumours. Bone Marrow Transplant 1992; 10 (suppl. 2): 28-29.
7. Shea TC, Storniolo AM, Mason JR et al. A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue. Semin Oncol 1992; 19: 139-144.
8. Motzer RJ, Gulati SC, Crown JP et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumours. Cancer 1992; 69: 550-556.
9. Guimaraes A, O'Reilly SM, Camba L et al. Escalating doses of VP16, cyclophosphamide and carboplatin as conditioning regimen for BMT in solid tumours. Eighteenth Annual Meeting of the European Group for Bone Marrow Transplantation; 1992, (abstr. 313) 182.
10. Broun ER, Nichols CR, Tricot G et al. High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumours. Bone Marrow Transplant 1991; 7: 53-56.
11. Lotz JP, Machover D, Malassagne B et al. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin. ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumours. J Clin Oncol 1991; 9: 1860-1870.
12. Barnett MJ, Coppin CML. Murray N et al. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours. Br J Cancer 1993; 68: 594-598.
13. Beyer J, Grabbe J, Lenz K et al. Cutaneous toxicity of high-dose carboplatin, etoposide and ifosfamide followed by autologous stem cell reinfusion. Bone Marrow Transplant 1992; 10: 491-494.
14. Fields KK, Elfenbein GJ, Saleh RA et al. Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma. Hematol Oncol 1992; 10: 61-74.
15. Rosti G, Albertazzi L, Salvioni R et al. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumours: A phase II study. Ann Oncol 1992; 3: 809-812.
16. Wilson WH, Jain V, Bryant G et al. Phase I and II study of high-dose ifosfamide. carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumours. J Clin Oncol 1992; 10: 1712-1722.
17. Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. J Clin Oncol 1994; 12: 1223-1231.
18. Barnett MJ, Swenerton KD, Hoskins PJ et al. Intensive therapy with carboplatin. etoposide and melphalan and autologous stem cell transplantation for epithelial ovarian carcinoma. Proc ASCO 1990; 9: 168 (abstr. 654).
19. Skov KA, Adomat J, Konway D, Farrell NP. Assessment of DNA binding of platinum-radiosensitiser complexes by inhibition of restriction enzymes. Chem Biol Interactions 1987; 62: 117-129.
20. O'Brien MER, Tonge K, Blake P et al. Blindness associated with high-dose carboplatin. Lancet 1992; 339: 558.
21. Cunningham D, Paz-Ares L, Milan L et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-763.
22. Wolff SN, Fer M, McKay CM et al. High dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J Clin Oncol 1983; 1: 701-705.
23. D'Incalci M, Rossi C, Zucchetti M et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986; 46: 2566-2571.
24. Pfuger KH, Schmidt L, Merkel M et al. Drug monitoring of etoposide (VP16-213). Cancer Chemother Pharmacol 1987; 20: 59-66.
25. Braverman AC, Antin JH. Plappert MT et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-1223.
26. Goren MP, Wright RK. Pratt CB et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatnum(II) therapy. Cancer Res 1987; 47: 1457-1460.
27. Quezado ZMN, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993; 118: 31-36.
28. Sorensen BT, Stromgren A, Jakobsen P et al. Renal handling of carboplatin. Cancer Chemother Pharmacol 1992; 30: 317-320.
29. Calvert AH, Newell DR, Gore E. Future directions and carboplatin: can therapeutic monitoring, high-dose administration, and hematologic support with growth factors expand the spectrum compared with cisplatin? Semin Oncol 1992; 19: 155-163.
30. Sleijfer DT, Smit EF, Meijer S et al. Acute and cumulative effects of carboplatin on renal function. Br J Cancer 1989; 60: 116-120.
31. Meyers FJ, Welborn J. Lewis JP, Flynn N. Infusion carboplatin treatment of relapsed and refractory acute leukaemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 1989; 7: 173-178.
32. Egorin MJ, van Echo DA, Tipping SJ et al. Pharmacokinetics and dose reduction of cis-diammine(1,1-cyclo-butane-dicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984; 44: 5432-5438.
33. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncal 1989; 7: 1748-1756.